Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

62 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

WTZ-GIST-09-01 (Imatinib + LBH589) Prior Antineoplastic Treatment 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Prior Antineoplastic Treatment 2009-011417-24

- 23/11/16 - 1 formulario, 2 itemgroups, 14 items, 1 idioma
Itemgroups: Prior Antineoplastic Treatment - Chemotherapy, Prior Antineoplastic Treatment - Surgery
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 1 Week 3 (V4) 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 1 Week 3 (V4) 2009-011417-24

- 23/11/16 - 1 formulario, 1 itemgroup, 15 items, 1 idioma
Itemgroup: Vital signs
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

S0502 Baseline Abnormalities Form NCT00324987

- 5/7/15 - 1 formulario, 2 itemgroups, 12 items, 1 idioma
Itemgroups: Header, Adverse event assessment
S0502 Baseline Abnormalities Form NCT00324987 S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FCBF779E-AB7C-7258-E034-0003BA3F9857

S0502 Notice of Death NCT00324987

- 3/7/15 - 1 formulario, 4 itemgroups, 22 items, 1 idioma
Itemgroups: Header, Date of death, CAUSES OF DEATH, Comments
S0502 Notice of Death NCT00324987 S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FCCFDBA1-76C9-4428-E034-0003BA3F9857

NCT00324987 Southwest Oncology Group Registration Form (S0502 Registration Step 2)

- 27/6/15 - 1 formulario, 2 itemgroups, 17 items, 1 idioma
Itemgroups: Header, Patient demographics
NCT00324987 Southwest Oncology Group Registration Form (S0502 Registration Step 2) S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=398E9509-E384-0DBF-E044-0003BA3F9857

S0502 Advanced GIST PreStudy Form NCT00324987

- 12/6/15 - 1 formulario, 7 itemgroups, 58 items, 1 idioma
Itemgroups: Header, Eligibility Verification, Cardiovascular/ Gastrointestinal Event, Current Disease Status, Patient History, Prior Treatment Related to this Cancer, Comments
S0502 Advanced GIST PreStudy Form NCT00324987 S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FCBF6A0D-F933-70F8-E034-0003BA3F9857

S0502 Post-Protocol Treatment Form NCT00324987

- 9/6/15 - 1 formulario, 3 itemgroups, 14 items, 1 idioma
Itemgroups: Header, Off-protocol treatment, Comments
S0502 Post-Protocol Treatment Form NCT00324987 S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FCBE8A3B-24A0-73D4-E034-0003BA3F9857

S0502 Baseline Tumor Assessment Form NCT00324987

- 9/6/15 - 1 formulario, 4 itemgroups, 20 items, 1 idioma
Itemgroups: Header, Evaluation of lesions, Diagnostic tests, COMMENTS
S0502 Baseline Tumor Assessment Form NCT00324987 S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FCCFE52A-AF63-4514-E034-0003BA3F9857

S0502 Follow-Up Tumor Assessment Form NCT00324987

- 9/6/15 - 1 formulario, 7 itemgroups, 33 items, 1 idioma
Itemgroups: Header, TARGET LESIONS, NON-TARGET DISEASE, Intranodular Recurrence, NEW LESIONS (specify site), Symptomatic deterioration, Comments
S0502 Follow-Up Tumor Assessment Form NCT00324987 S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FCCFDEC1-66B9-4478-E034-0003BA3F9857

S0502 Positron Emission Tomography (PET) Assessment Form NCT00324987

- 9/6/15 - 1 formulario, 3 itemgroups, 22 items, 1 idioma
Itemgroups: Header, Positron Emission Tomography (PET) Assessment, Comments
S0502 Positron Emission Tomography (PET) Assessment Form NCT00324987 S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FCBE8452-90FE-734C-E034-0003BA3F9857

Gastrointestinal Stromal Tumor NCT00324987 - Off Treatment Notice Gastrointestinal Stromal Tumor S0502 NCT00324987

- 24/3/15 - 1 formulario, 2 itemgroups, 28 items, 1 idioma
Itemgroups: Header, OFF TREATMENT
S0502 Off Treatment Notice S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor NCT00324987 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FCCFD537-4859-4344-E034-0003BA3F9857

Gastrointestinal Stromal Tumor NCT00324987 Toxicity - S0502 Adverse Event Form - 2320351v1.0 - S0502 Adverse Event Form

- 9/1/15 - 1 formulario, 3 itemgroups, 19 items, 1 idioma
Itemgroups: Header, Adverse Events, Comments
S0502 Adverse Event Form S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FCBF7FD7-A1A5-7312-E034-0003BA3F9857

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial